<?xml version="1.0" encoding="UTF-8"?>
<p>Patients were excluded if they had any of the following: t(9;22) cytogenetic translocation, acute promyelocytic leukemia, hyperleukocytosis (leukocytes ≥30 × 10
 <xref rid="ajh25238-bib-0009" ref-type="ref">9</xref>/L) at screening (hydroxyurea or leukopheresis were allowed before and up to 1 week after first dose of glasdegib for control of rapidly progressing leukemia), or known active leukemia in the central nervous system. Other exclusion criteria included: serum creatinine &gt;1.3 mg/dL, severe cardiac disease (eg, left‐ventricular ejection fraction &lt;45% by multiple gated acquisition or echocardiography at screening), or a cumulative anthracycline dose equivalent of ≥250 mg/m
 <sup>2</sup> of daunorubicin or ≥125 mg/m
 <sup>2</sup> of idarubicin.
</p>
